NCT03188705 is a Phase 4 clinical trial of Clopidogrel in Heart Diseases, sponsored by University of Maryland, Baltimore.

Who is sponsoring NCT03188705?

NCT03188705 is sponsored by University of Maryland, Baltimore.

What drugs are being tested in NCT03188705?

Interventions in NCT03188705: Clopidogrel, Aspirin.

What condition does NCT03188705 study?

NCT03188705 studies Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases, Myocardial Ischemia, Artery Occlusion, Aspirin Sensitivity, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Platelet Thrombus.

Is NCT03188705 still recruiting?

NCT03188705 is currently completed. Last updated 15 June 2023.

Are results published for NCT03188705?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-06-15 · How we verify

NCT03188705

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CES1 Carriers in the PAPI Study

Completed Phase 4 Results posted Last updated 15 June 2023

What this trial tests

Phase 4 trial testing Clopidogrel in Heart Diseases in 6 participants. Completed in 17 January 2020.

Timeline

14 October 2019

Primary endpoint
17 January 2020

17 January 2020

Quick facts

Lead sponsor	University of Maryland, Baltimore
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	6
Start date	14 October 2019
Primary completion	17 January 2020
Estimated completion	17 January 2020
Sites	1 location across United States

Drugs / interventions tested

Clopidogrel (clopidogrel) — full drug profile →
Aspirin — full drug profile →

Conditions studied

Heart Diseases — all drugs for Heart Diseases →
Coronary Disease — all drugs for Coronary Disease →
Coronary Artery Disease — all drugs for Coronary Artery Disease →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

University of Maryland, Baltimore

Who can join

20 and older, any sex, with Heart Diseases or Coronary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396). The purpose of this investigation is to assess the impact of genetic variation in the carboxylesterase 1 (CES1) on response to clopidogrel as well as dual antiplatelet therapy (i.e. clopidogrel and aspirin), as assessed by ex vivo platelet aggregometry, in healthy Amish individuals. The investigators hypothesize that participants who carry alleles that modify the activity or expression of CES1 will have altered response to clopidogrel as well as dual antiplatelet therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Clopidogrel

Trials testing the same drug.

NCT07012629 — A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in P · Phase 3 · recruiting
NCT07025148 — Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding · Phase 4 · recruiting
NCT07180472 — Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol · Phase 4 · not yet recruiting
NCT06757764 — The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis · Phase 4 · recruiting
NCT07040787 — Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects · Phase 1 · completed

Other recruiting trials for Heart Diseases

Currently open trials in the same condition.

NCT07288216 — Transition to KPL-387 Monotherapy Dosing & Administration Study · Phase 2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
NCT06954610 — Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation · recruiting
NCT06769880 — Use of Bedside Imaging and Community Health Workers for Early Screening and Referral of Pre-symptomatic Stage B Heart Fa · NA · recruiting

Other University of Maryland, Baltimore trials

Trials by the same sponsor.

NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03188705 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03188705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing